Literature DB >> 2890035

Somatostatin and symptomatic relief of irritable bowel syndrome.

N J Talley, I Turner, W R Middleton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890035     DOI: 10.1016/s0140-6736(87)91564-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Therapeutic potential of a long acting somatostatin analogue in gastrointestinal diseases.

Authors:  L J O'Donnell; M J Farthing
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

2.  Evaluation of individual symptoms cannot predict presence of gastric hypersensitivity in functional dyspepsia.

Authors:  P L Rhee; Y H Kim; H J Son; J J Kim; K C Koh; S W Paik; J C Rhee; K W Choi
Journal:  Dig Dis Sci       Date:  2000-08       Impact factor: 3.199

3.  Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone.

Authors:  M Bradette; M Delvaux; G Staumont; J Fioramonti; L Bueno; J Frexinos
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

Review 4.  Pharmacotherapy: non-serotonergic mechanisms.

Authors:  R Spiller
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 5.  Evaluation of drug treatment in irritable bowel syndrome.

Authors:  Nicholas J Talley
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 6.  New drugs in the management of the irritable bowel syndrome.

Authors:  M J Farthing
Journal:  Drugs       Date:  1998-07       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.